NuVasive to acquire Osteocel biologics business from Osiris Therapeutics
NuVasive, a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced that it has signed a definitive agreement to acquire the Osteocel biologics business from Osiris Therapeutics, Inc.
Astellas Pharma, a pharmaceutical company, and OSI Pharmaceuticals, a biotechnology company, have entered into a definitive merger agreement under which Astellas will acquire OSI.